David Vitter: Patent Pending

  • by: |
  • 03/22/2013

David Vitter: Wrong on Drug Importation. Wrong on Patent Settlements.

This overly vague language of Senator Vitter’s amendment (#628) to the Senate Budget Resolution would ban all forms of patent settlements, including those that the FTC and the courts have not opposed. This would prevent pro-consumer settlements, reduce the value of patents, and reduce incentives for innovation.  Instead, enforcement agencies and courts should continue to evaluate patent settlements on a case-by-case basis, under the same antitrust principles that apply to all other patent settlements.

The Supreme Court is currently addressing the issue, and Congress should await the Court’s ruling (likely this June) on the standard for reviewing such settlements.

For the first time the Supreme Court will review a case regarding the antitrust standard that should apply to patent settlements between innovator and generic pharmaceutical companies.  Given the complexities and the conflict between the circuits, even if legislators believe that Congressional action may be warranted, consideration of the issue should await the Supreme Court’s decision in the case. 

A ban is bad public policy that harms innovation.

Banning Hatch-Waxman patent settlements would increase the cost of patent enforcement, decrease the value of patent protection generally, and decrease incentives for taking the risks necessary to develop new medicines.  As one court has stated, “a rule prohibiting settlements of Hatch-Waxman litigation can have grave consequences for R&D and, in turn, severe consequences for consumers.”

A ban would delay generic entry and delay benefits to consumers. 

Despite what proponents of the legislation say, statistics show that brand companies have prevailed in approximately 52 percent of patent cases against generic challengers.

A win by the patent holder means the generic almost certainly would not be able to enter the market before the patent expires.  In many cases, therefore, settlements accelerate generic entry and provide access to lower cost medicines.  According to one generic company’s estimate, settlements on 10 products alone have resulted in more than $67 billion in savings to consumers. 

Congress has already given the Federal Trade Commission the ability to review and evaluate individual patent settlements. 

Unlike patent settlements in any other industry, Congress in 2003 required that brand and generic companies settling patent litigation arising out of the generic company’s patent challenge must file a copy of their settlement agreement or a written description of it with the FTC and the Department of Justice before the date when the generic product may enter the market.  The FTC thus has the power to challenge any agreement that it deems anticompetitive. 

A ban on an entire category of settlements is unwarranted.  This kind of blanket ban is overly broad and could negatively impact the availability of medicines that help patients live longer, healthier lives.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog